title: BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia.
abstract: BCL6 is a zinc-finger transcriptional repressor known for its oncogenic role in B cell lymphoma. In a recent issue of Nature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph(+) acute lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors.
authors: Molecular Oncology Research Institute, Division of Hematology/Oncology, Tufts Medical Center, Boston, MA 02111, USA. rvanetten@tuftsmedicalcenter.org
authors: Richard A
authors: RA
authors: Van Etten